Immune Thrombocytopenic Purpura (ITP) MCQ Quiz | Hematology

Welcome to the Hematology quiz on Immune Thrombocytopenic Purpura (ITP). This quiz is designed for MBBS students to test and reinforce their understanding of the pathophysiology, clinical features, diagnosis, and management of ITP. You will be presented with 25 multiple-choice questions covering key concepts essential for your curriculum. This interactive assessment will help you identify areas of strength and those requiring further study. After submitting your answers, you will receive your total score, and the correct and incorrect answers will be highlighted for immediate feedback. You can also download a PDF copy of all the questions along with their correct answers for future reference and revision. Good luck!

1. What is the primary pathophysiological mechanism in Immune Thrombocytopenic Purpura (ITP)?

2. A 28-year-old female presents with petechiae and epistaxis. Her platelet count is 18,000/µL. Which of the following findings on physical examination would make a diagnosis of ITP less likely?

3. What is the most common first-line therapy for a newly diagnosed adult with symptomatic ITP and a platelet count below 30,000/µL?

4. In ITP, the autoantibodies are most commonly directed against which platelet surface glycoproteins?

5. A 5-year-old child presents with sudden onset of bruising and petechiae 2 weeks after a viral upper respiratory infection. Platelet count is 15,000/µL. What is the most likely prognosis?

6. Which investigation is crucial to perform in an older adult (>60 years) presenting with ITP-like symptoms to rule out other underlying pathologies?

7. For a patient with ITP and life-threatening intracranial hemorrhage, what is the most appropriate immediate management?

8. What is the primary mechanism of action of Intravenous Immunoglobulin (IVIG) in the treatment of ITP?

9. Which of the following is a key characteristic of a peripheral blood smear in a patient with typical ITP?

10. Splenectomy is a second-line treatment for ITP. After this procedure, patients are at a lifelong increased risk of infection from which type of organisms?

11. Thrombopoietin receptor agonists (TPO-RAs) like romiplostim and eltrombopag are used in chronic ITP. What is their mechanism of action?

12. Which of the following conditions is NOT a known cause of secondary ITP?

13. The diagnosis of ITP is primarily one of:

14. Rituximab, an anti-CD20 monoclonal antibody, is used in refractory ITP. Its therapeutic effect is achieved by:

15. What is the usual finding for Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT) in a patient with primary ITP?

16. In which patient population is a “watch and wait” or observation-only approach most appropriate for ITP?

17. A patient with chronic ITP fails to respond to corticosteroids and IVIG. Splenectomy is planned. Which vaccinations are essential before the procedure?

18. The term “chronic ITP” is used when thrombocytopenia persists for more than:

19. Why are platelet transfusions generally avoided in routine management of ITP unless there is life-threatening bleeding?

20. Which of the following conditions presents with microangiopathic hemolytic anemia, thrombocytopenia, fever, renal dysfunction, and neurological symptoms, and can be a key differential for ITP?

21. What is the expected bone marrow finding in a patient with ITP?

22. Management of ITP in a pregnant woman with a platelet count of 20,000/µL in the third trimester would most likely involve:

23. Which drug is known to be associated with drug-induced immune thrombocytopenia that mimics ITP?

24. A major concern with long-term high-dose corticosteroid use for chronic ITP is:

25. What differentiates ITP from Bernard-Soulier syndrome, another cause of thrombocytopenia and large platelets?